New combo aims to shrink lung tumors before surgery
NCT ID NCT07354061
First seen Jan 21, 2026 · Last updated Jun 16, 2026 · Updated 25 times
Summary
This study tests whether a targeted drug (ensartinib) combined with standard chemotherapy can shrink ALK-positive lung cancer tumors before surgery. About 20 adults with stage II-IIIB lung cancer will receive the combo for 9 weeks, then have their tumor removed. Researchers will check how many tumors completely disappear and monitor side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NSCLC (NON-SMALL CELL LUNG CANCER) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Tangdu Hospital
RECRUITINGXi’an, Shanxi, 710038, China
Contact Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.